The liver is the sixth most common site of primary cancer in humans and the fourth leading
cause of cancer‐related death in the world. Hepatocellular carcinoma (HCC) accounts for …

Hepatocellular carcinoma (HCC) is a prevalent disease with a progression that is modulated
by the immune system. Systemic therapy is used in the advanced stage and until 2017 …

Liver metastases are commonly detected in a range of malignancies including colorectal
cancer (CRC), pancreatic cancer, melanoma, lung cancer and breast cancer, although CRC …

Hepatocellular carcinoma (HCC) is associated with chronic inflammation and fibrosis arising
from different etiologies, including hepatitis B and C and alcoholic and nonalcoholic fatty …

Liver cancer is the second leading cause of cancer mortality worldwide, causing more than
700,000 deaths annually. Because of the wide landscape of genomic alterations and limited …

Hepatocellular carcinoma (HCC) is one of the most aggressive types of cancer and lacks
effective therapeutic approaches. Most HCC develops in the setting of chronic liver injury …

Regulatory myeloid immune cells, such as myeloid-derived suppressor cells (MDSCs),
populate inflamed or cancerous tissue and block immune cell effector functions. The lack of …

Advanced hepatocellular carcinoma (HCC) is a serious therapeutic challenge and targeted
therapies only provide a modest benefit in terms of overall survival. Novel approaches are …

Hepatocellular carcinoma (HCC) is the third most frequent cause of cancer-related death.
The immune-rich contexture of the HCC microenvironment makes this tumour an appealing …

The emergence of disseminated metastases remains the primary cause of mortality in
cancer patients. Formation of the pre-metastatic niche (PMN), which precedes the …